ClearPoint Neuro, Inc.
CLPT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 3.18 | -1.37 | -1.74 |
| FCF Yield | -0.54% | -0.78% | -1.93% | -0.36% |
| EV / EBITDA | -116.98 | -64.89 | -55.01 | -77.76 |
| Quality | ||||
| ROIC | -10.02% | -10.18% | -25.91% | -19.07% |
| Gross Margin | 63.20% | 60.29% | 60.48% | 61.28% |
| Cash Conversion Ratio | 0.53 | 0.44 | 1.02 | 0.23 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.44% | 15.68% | 15.44% | 15.16% |
| Free Cash Flow Growth | -25.61% | 58.41% | -321.98% | -24.36% |
| Safety | ||||
| Net Debt / EBITDA | 0.47 | 1.19 | 1.54 | 3.22 |
| Interest Coverage | -9.72 | -71.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.50 | 0.58 | 0.51 | 0.44 |
| Cash Conversion Cycle | 202.36 | 158.74 | 182.76 | 219.78 |